Results 21 to 30 of about 58,938 (145)

Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?

BMC Nephrology, 2012
Background Dual renin-angiotensin system blockade with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been advocated to minimize proteinuria. However, recent trials have questioned the renal safety of this approach.
Fernandez-Fernandez Beatriz, Ortiz Alberto, Gomez-Guerrero Carmen, Barat Antonio, Martín-Cleary Catalina, Egido Jesús   +5 more
doaj   +1 more source

Dihydropyridine Calcium Channel Blocker Therapy and Risk of CKD Progression in Type 2 Diabetes Treated With Renin Angiotensin System Inhibitors and SGLT2 Inhibitors: A Real-World Retrospective Cohort Study

Kidney Medicine
Rationale & Objective: Optimal antihypertensive therapy with renoprotective effects is essential to slow diabetic kidney disease progression. We evaluated the impact of dihydropyridine calcium channel blockers on kidney outcomes in patients with type
Timna Agur, Tali Steinmetz, Shira Goldman, Boris Zingerman, Dana Bielopolski, Eviatar Nesher, Ittai Fattal, Eshcar Meisel, Benaya Rozen-Zvi   +8 more
doaj   +1 more source

Present and Future in the Treatment of Diabetic Kidney Disease

Journal of Diabetes Research, 2015
Diabetic kidney disease is the leading cause of end-stage renal disease. Albuminuria is recognized as the most important prognostic factor for chronic kidney disease progression.
Borja Quiroga, David Arroyo, Gabriel de Arriba   +2 more
doaj   +1 more source

P4.18 ANTIHYPERTENSIVE ACTIVITY OF LONG CHAIN FATTY ACID DERIVATIVES OF FLAVONOIDS VIA INHIBITION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS)

Artery Research, 2013
Hypertension is a contributing factor to pathophysiology of vascular damage and accelerated arterial stiffening. Renin-angiotensin-aldosterone system (RAAS) inhibitors are widely used for treatment of persistent hypertension.
Bhullar Khushwant Singh, Zia ullah, Rupasinghe Vasantha   +2 more
doaj   +1 more source

Targetable NOTCH1 rearrangements in reninoma

Nature Communications, 2023
Reninomas are exceedingly rare renin-secreting kidney tumours that derive from juxtaglomerular cells, specialised smooth muscle cells that reside at the vascular inlet of glomeruli.
Taryn D. Treger, John E. G. Lawrence, Nathaniel D. Anderson, Tim H. H. Coorens, Aleksandra Letunovska, Emilie Abby, Henry Lee-Six, Thomas R. W. Oliver, Reem Al-Saadi, Kjell Tullus, Guillaume Morcrette, J. Ciaran Hutchinson, Dyanne Rampling, Neil Sebire, Kathy Pritchard-Jones, Matthew D. Young, Thomas J. Mitchell, Philip H. Jones, Maxine Tran, Sam Behjati, Tanzina Chowdhury   +20 more
doaj   +1 more source

Renin as a target of direct pharmacological block in arterial hypertension

Терапевтический архив, 2009
Renin is a basic component of renin-angiotensin-aldosteron system which contributes much to the activity of this system. Renin and its precursor prorenin can interact with prorenin receptors thus inducing hypertrophy and fibrogenesis in target tissues ...
Nikolay Alekseevich Mukhin, V V Fomin, N A Mukhin, V V Fomin   +3 more
doaj  

New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Mineralocorticoid-Receptor Blockers Exert Antihypertensive and Renoprotective Effects Independently of the Renin–Angiotensin System

Journal of Pharmacological Sciences, 2010
The role of angiotensin II in mediating hypertension and renal diseases is well documented, and inhibition of the renin–angiotensin–aldosterone system elicits antihypertensive and renoprotective effects.
Akira Nishiyama, Koichi Hasegawa, Suwarni Diah, Hirofumi Hitomi   +3 more
doaj   +1 more source

Aliskiren – an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension

Vascular Health and Risk Management, 2008
Kristina AllikmetsDepartment of Drug Development and Medical Affairs, Nycomed Group, Roskilde, DenmarkAbstract: The importance of renin-angiotensin-aldosterone system (RAAS) in diseases such as hypertension, congestive heart failure and chronic renal ...
Kristina Allikmets
doaj  

The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism

Frontiers in Pharmacology, 2021
Primary aldosteronism (PA) is a potentially curable form of secondary hypertension caused by excessive renin-independent aldosterone secretion, leading to increased target organ damage and cardiovascular morbidity and mortality.
Piotr Jędrusik, Bartosz Symonides, Jacek Lewandowski, Zbigniew Gaciong   +3 more
doaj   +1 more source

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy

Vascular Health and Risk Management, 2008
Kalathil K SureshkumarDivision of Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, Pennsylvania, USAAbstract: Hypertension is a major risk factor for the development of cardiovascular and renal disease.
Kalathil K Sureshkumar
doaj